Dexanabinol

Dexanabinol
Dexanabinol
Systematic (IUPAC) name
(6aS,10aS)-9-(Hydroxymethyl)- 6,6-dimethyl- 3-(2-methyloctan-2-yl)- 6a,7,10,10a-tetrahydrobenzo [c]chromen-1-ol
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 112924-45-5
ATC code None
PubChem CID 107778
UNII R6VT8U5372 YesY
Chemical data
Formula C25H38O3 
Mol. mass 386.567 g/mol
 YesY(what is this?)  (verify)

Dexanabinol (HU-211) is a synthetic cannabinoid derivative, which is the "unnatural" enantiomer of the potent cannabinoid agonist HU-210.[1] Unlike other cannabinoid derivatives, HU-211 does not act as a cannabinoid receptor agonist, but instead has NMDA antagonist effects.[2] It therefore does not produce cannabis-like effects, but is anticonvulsant and neuroprotective, and is widely used in scientific research as well as currently being studied for practical applications such as treatment of head injury or stroke.[3][4][5] It was shown to be safe in clinical trials.[6]

References

  1. ^ Pop E (September 2000). "Nonpsychotropic synthetic cannabinoids". Current Pharmaceutical Design 6 (13): 1347–60. doi:10.2174/1381612003399446. PMID 10903397. 
  2. ^ Feigenbaum JJ, Bergmann F, Richmond SA, Mechoulam R, Nadler V, Kloog Y, Sokolovsky M (December 1989). "Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker". Proceedings of the National Academy of Sciences of the United States of America 86 (23): 9584–7. doi:10.1073/pnas.86.23.9584. PMC 298542. PMID 2556719. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=298542. 
  3. ^ Biegon A, Joseph AB (August 1995). "Development of HU-211 as a neuroprotectant for ischemic brain damage". Neurological Research 17 (4): 275–80. PMID 7477742. 
  4. ^ Darlington CL (October 2003). "Dexanabinol: a novel cannabinoid with neuroprotective properties". IDrugs : the Investigational Drugs Journal 6 (10): 976–9. PMID 14534855. 
  5. ^ Vink R, Nimmo AJ (January 2009). "Multifunctional drugs for head injury". Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics 6 (1): 28–42. doi:10.1016/j.nurt.2008.10.036. PMID 19110197. 
  6. ^ Maas AI, Murray G, Henney H, et al. (January 2006). "Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial". Lancet Neurol 5 (1): 38–45. doi:10.1016/S1474-4422(05)70253-2. PMID 16361021. 
Stub icon This pharmacology-related article is a stub. You can help Wikipedia by expanding it. This cannabinoid related article is a stub. You can help Wikipedia by expanding it.